Yun-Sik Dho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yun-Sik Dho has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Heon Yoo
Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea
7 shared publications - Ho-Shin Gwak
National Cancer Center 5 Neuro-oncology clinic Goyang, Republic of Korea
6 shared publications - Kyu-Chang Wang
Neuro-oncology Clinic, Center for Rare Cancers, National Cancer Center, Goyang, Republic of Korea
6 shared publications - Sang-Hoon Shin
Neuro-Oncology Clinic, National Cancer Center, Goyang, Korea
5 shared publications - Jiyoun Choi
R&D center, CellabMED Inc., Seoul, Republic of Korea
4 shared publications - Ju-Hwang Park
CGT center, CellabMED Inc., Seoul, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (6) , 855-865
Targeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology
Advancement of molecular targeted therapies has revolutionized the treatment of several challenging and previously refractory tumors. Since the introduction of rituximab in 1997, the field of molecular targeted agents have continued to evolve. Notably, vorasidenib, a brainpenetrant dual inhibitor of mutant isocitrate dehydrogenase (IDH) 1 and 2, has recently demonstrated promising results in the 2023 INDIGO trials with improved progression-free survival and delayed need for subsequent interventions in patients with IDH-mutant low-grade gliomas. Although therapeutic options for glioma have long remained largely limited to surgery, radiation, and conventional chemotherapy despite extensive and ongoing research, the advent of vorasidenib opens a new chapter in glioma treatment. This review summarizes the key clinical studies of vorasidenib and discusses its potential role, limitations, and future directions in the evolving treatment paradigm of IDH-mutant gliomas.
- 1 November 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (6) , 855-865
Open AccessTargeting Isocitrate Dehydrogenase-Mutant Glioma with Vorasidenib : A New Era in Precision Neuro-Oncology
Advancement of molecular targeted therapies has revolutionized the treatment of several challenging and previously refractory tumors. Since the introduction of rituximab in 1997, the field of molecular targeted agents have continued to evolve. Notably, vorasidenib, a brainpenetrant dual inhibitor of mutant isocitrate dehydrogenase (IDH) 1 and 2, has recently demonstrated promising results in the 2023 INDIGO trials with improved progression-free survival and delayed need for subsequent interventions in patients with IDH-mutant low-grade gliomas. Although therapeutic options for glioma have long remained largely limited to surgery, radiation, and conventional chemotherapy despite extensive and ongoing research, the advent of vorasidenib opens a new chapter in glioma treatment. This review summarizes the key clinical studies of vorasidenib and discusses its potential role, limitations, and future directions in the evolving treatment paradigm of IDH-mutant gliomas.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose:This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods:Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results:Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions:Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose:This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods:Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results:Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions:Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Eligibility criteria S2.Representativeness of study participants S3.Patients’characteristics S4. Release criteria S5. Immunophenotypic composition S6. Individual CAR-T transgene copy number S7. pharmacokinetic parameters in blood S8. Individual patient serum cytokine S9. Median peak time and peak fold change of serum cytokines S10.Individual patient CSF cytokine levels S11. Baseline tumor size and longitudinal radiographic changes
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Eligibility criteria S2.Representativeness of study participants S3.Patients’characteristics S4. Release criteria S5. Immunophenotypic composition S6. Individual CAR-T transgene copy number S7. pharmacokinetic parameters in blood S8. Individual patient serum cytokine S9. Median peak time and peak fold change of serum cytokines S10.Individual patient CSF cytokine levels S11. Baseline tumor size and longitudinal radiographic changes
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Characteristics of infused YYB-103 S2. MRI of A3-03 S3. Pheripheral blood lymphocyte level S4. Serum testosterone level S5. In vivo expansion profile of YYB-103 in blood and CSF S6. Serum and CSF cytokine profiles S7. Correlation between pheripheral blood CAR-T expansion and longitudinal radiographic changes S8. MRI of A1-03
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures1 from Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
S1. Characteristics of infused YYB-103 S2. MRI of A3-03 S3. Pheripheral blood lymphocyte level S4. Serum testosterone level S5. In vivo expansion profile of YYB-103 in blood and CSF S6. Serum and CSF cytokine profiles S7. Correlation between pheripheral blood CAR-T expansion and longitudinal radiographic changes S8. MRI of A1-03
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4656-4667
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose: This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods: Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results: Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions: Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- 4 August 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4656-4667
Phase I Trial of IL13Rα2-Targeted CAR T-cell Therapy for Recurrent Malignant Glioma: Clinical Results and Pharmacokinetics
Purpose: This single-center, open-label, phase I trial evaluated the safety and tolerability of chimeric antigen receptor (CAR) T cells targeting interleukin 13 receptor α2 (IL13Rα2) in patients with malignant gliomas. Patients and Methods: Adults with World Health Organization grade 3 to 4 gliomas, recurrent after standard treatment and expressing IL13Rα2 (confirmed by immunohistochemistry), received a single intravenous infusion of autologous CAR T cells. Primary objectives were to measure the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included assessment of pharmacokinetics, objective response rate, progression-free survival (PFS), and overall survival (OS). Results: Ten patients were sequentially assigned to 3 dosing cohorts (1 × 107, 3 × 107, and 1 × 108 cells/kg). The MTD was not reached, as no dose-limiting toxicities were observed, and all adverse events (AE) were grade ≤3 without irreversible sequelae. The most common treatment-related AE were pyrexia (70%) and elevated transaminase (70%). CAR T-cell levels in blood reached peak concentrations at a median of 7 days (range, 3–14), and the transgene was detected in cerebrospinal fluid from 5 of 6 patients treated at the higher 2 doses. Nine patients were evaluable for survival analysis, among whom 6 were available for response assessment at 3 months; best response was stable disease in 3 cases. The median PFS was 2.6 months [95% confidence interval (CI), 0.95–5.75], and the median OS was 10.9 months (95% CI, 8.2–26.6). Conclusions: Intravenous IL13Rα2-targeted CAR T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing and preconditioning regimens and identify exploratory biomarkers for efficacy evaluation.
- Open Access
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (4) , 199-206
Targeting Hypoxia-Inducible Factor Signaling in von Hippel–Lindau Disease: Belzutifan as a Disease-Modifying Therapy
Lee C, et al. Brain Tumor Res Treat. 2026 Oct;14(4):199-206. https://doi.org/10.14791/btrt.2026.0009
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (4) , 199-206
Open AccessTargeting Hypoxia-Inducible Factor Signaling in von Hippel–Lindau Disease: Belzutifan as a Disease-Modifying Therapy
Lee C, et al. Brain Tumor Res Treat. 2026 Oct;14(4):199-206. https://doi.org/10.14791/btrt.2026.0009
- Open Access
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (3) , 137-146
Descriptive Analysis of Surgically Resected Pure Radiation Necrosis After Radiation Therapy for Brain Metastasis: Clinical Features, MRI Findings, and Outcomes
Kim RH, et al. Brain Tumor Res Treat. 2026 Jul;14(3):137-146. https://doi.org/10.14791/btrt.2026.0029
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (3) , 137-146
Open AccessDescriptive Analysis of Surgically Resected Pure Radiation Necrosis After Radiation Therapy for Brain Metastasis: Clinical Features, MRI Findings, and Outcomes
Kim RH, et al. Brain Tumor Res Treat. 2026 Jul;14(3):137-146. https://doi.org/10.14791/btrt.2026.0029
- Open Access
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (1) , 35-46
Fate of Brain Metastasis With Cerebrospinal Fluid Space Invasion Based on MRI Findings: Clinical Features and Factors Affecting Progression to Overt Leptomeningeal Metastasis
Parenchymal brain metastasis (BM) and its extended growth into cerebrospinal fluid (CSF) pathways or surgical spillage could result in leptomeningeal metastasis (LM). We defined BM with epipial spread or dural attachment on MRI as BM with CSF space invasion (BM-CSFi), regardless of CSF cytology results, and evaluated its clinical course after BM resection. We retrospectively reviewed 297 patients who underwent craniotomy for BM excluding patients followed for p=0.002), primary small cell lung cancer (HR, 4.92; p=0.026), infratentorial BM location (HR, 2.14; p=0.019), and postoperative cumulative CSF cytology positive rate ≥50% (HR, 7.13; p=0.012) were independent risk factors for LM progression. The mode of resection and postoperative radiotherapy or systemic chemotherapy were not significantly associated with LM progression. BM-CSFi, defined by preoperative MRI findings, may represent a clinically important precursor of LM. Our findings highlight the need for close monitoring of patients with BM-CSFi and the development of management protocols to minimize the risk of LM progression.
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (1) , 35-46
Open AccessFate of Brain Metastasis With Cerebrospinal Fluid Space Invasion Based on MRI Findings: Clinical Features and Factors Affecting Progression to Overt Leptomeningeal Metastasis
Parenchymal brain metastasis (BM) and its extended growth into cerebrospinal fluid (CSF) pathways or surgical spillage could result in leptomeningeal metastasis (LM). We defined BM with epipial spread or dural attachment on MRI as BM with CSF space invasion (BM-CSFi), regardless of CSF cytology results, and evaluated its clinical course after BM resection. We retrospectively reviewed 297 patients who underwent craniotomy for BM excluding patients followed for p=0.002), primary small cell lung cancer (HR, 4.92; p=0.026), infratentorial BM location (HR, 2.14; p=0.019), and postoperative cumulative CSF cytology positive rate ≥50% (HR, 7.13; p=0.012) were independent risk factors for LM progression. The mode of resection and postoperative radiotherapy or systemic chemotherapy were not significantly associated with LM progression. BM-CSFi, defined by preoperative MRI findings, may represent a clinically important precursor of LM. Our findings highlight the need for close monitoring of patients with BM-CSFi and the development of management protocols to minimize the risk of LM progression.
- Open Access
- 23 July 2025
- Published by Elsevier in World Neurosurgery
- p. 124300
Developing deep learning-based cerebral ventricle auto-segmentation system and clinical application for the evaluation of ventriculomegaly
- 23 July 2025
- Published by Elsevier in World Neurosurgery
- p. 124300
Open AccessDeveloping deep learning-based cerebral ventricle auto-segmentation system and clinical application for the evaluation of ventriculomegaly
- Open Access
- 4 November 2024
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (2) , 137-149
Envisioning the Future of the Neurosurgical Operating Room with the Concept of the Medical Metaverse
The medical metaverse can be defined as a virtual spatiotemporal framework wherein higher-dimensional medical information is generated, exchanged, and utilized through communication among medical personnel or patients. This occurs through the integration of cutting-edge technologies such as augmented reality (AR), virtual reality (VR), artificial intelligence (AI), big data, cloud computing, and others. We can envision a future neurosurgical operating room that utilizes such medical metaverse concept such as shared extended reality (AR/VR) of surgical field, AI-powered intraoperative neurophysiological monitoring, and real-time intraoperative tissue diagnosis. The future neurosurgical operation room will evolve into a true medical metaverse where participants of surgery can communicate in overlapping virtual layers of surgery, monitoring, and diagnosis.
- 4 November 2024
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (2) , 137-149
Open AccessEnvisioning the Future of the Neurosurgical Operating Room with the Concept of the Medical Metaverse
The medical metaverse can be defined as a virtual spatiotemporal framework wherein higher-dimensional medical information is generated, exchanged, and utilized through communication among medical personnel or patients. This occurs through the integration of cutting-edge technologies such as augmented reality (AR), virtual reality (VR), artificial intelligence (AI), big data, cloud computing, and others. We can envision a future neurosurgical operating room that utilizes such medical metaverse concept such as shared extended reality (AR/VR) of surgical field, AI-powered intraoperative neurophysiological monitoring, and real-time intraoperative tissue diagnosis. The future neurosurgical operation room will evolve into a true medical metaverse where participants of surgery can communicate in overlapping virtual layers of surgery, monitoring, and diagnosis.